Expert Systems Inc., a leading drug discovery accelerator, proudly announces the Series A funding and launch of Mondego Bio, an emerging immuno-oncology company headquartered at Biocant Park in Ca...
The new venture is backed by Biovance Capital, Torrey Pines Investment, and OrbiMed. Mondego Bio is advancing a portfolio of first- and best-in-class PTPN2 inhibitors designed to transform cancer immunotherapy.
SAN DIEGO, Sept. 29, 2025 /PRNewswire/ -- Mondego Bio is strategically positioned to address one of oncology's biggest challenges: overcoming immune resistance in solid tumors. Its proprietary PTPN2 inhibitors combine oral bioavailability, high selectivity, and favorable safety and tolerability profiles, supporting their potential as best-in-class agents for combination immuno-oncology regimens. These drug candidates were designed and optimized using Expert Systems' AI/ML-driven molecular design and predictive pharmacology platform, dramatically accelerating the path from concept to clinical readiness.
"Solid tumors remain one of the greatest unmet needs in medicine," said Dr. Tudor Oprea, CEO of Expert Systems Inc. "By integrating predictive ADMET and PK/PD modeling with in-silico and in vitro new-approach methodologies (NAMs), we gave Mondego Bio a decisive edge — identifying high-potential PTPN2 inhibitors and accelerating their journey into development.."
Expert Systems will continue to provide strategic, scientific, and technological support as Mondego Bio advances its pipeline into first-in-human studies. This collaboration highlights Expert Systems' unique ability to create and scale high-value biotech ventures, de-risking early-stage innovation for investors and partners.
About Expert Systems Inc.
Expert Systems Inc. is a life sciences accelerator dedicated to launching tomorrow's breakthrough therapies. Its AI/ML-powered platforms span the full biotech lifecycle: ideation, rational drug design, financing, preclinical and clinical development, NAMs, regulatory strategy, and market positioning and partnering support.
With a proven track record of creating multiple Seed and Series A companies, Expert Systems has supported over 30 R&D programs funded by institutional investors and strategic partners across North America, Europe, and Australia. By shortening timelines from in silico discovery to first-in-human trials, Expert Systems delivers compelling, investable biotech opportunities with clear exit pathways.
For more information, visit www.expertsystems.inc.
Media Contact:
Bill Farley, CBO
Expert Systems Inc.
bfarley@expertsystems.inc
View original content to download multimedia:https://www.prnewswire.com/news-releases/expert-systems-inc-a-leading-drug-discovery-accelerator-proudly-announces-the-series-a-funding-and-launch-of-mondego-bio-an-emerging-immuno-oncology-company-headquartered-at-biocant-park-in-cantanhede-portugal-302569395.html
SOURCE Expert Systems, Inc.